GSK launches Phase III study of Respiratory Syncytial Virus (RSV) vaccine in pregnant mothers

The GRACE study, which follows publication of positive phase I/II data, will involve up to 10,000 pregnant women aged 19-45 years, and will evaluate the efficacy of a single dose for prevention of medically assessed RSV-associated lower respiratory tract infections in newborns.

Source:

PharmaTimes